LearnGlossaryMarketStocksSuperinvestorsSign in

BNTX

BioNTech SE

Healthcare · $24.8B market cap

Verdict

We can't put a fair value on BNTX right now. It has fewer than 5 profitable years and uneven cash flow, not enough history to project from yet.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth-69.7% a year✗
Equity per share growth0.5% a year✗
Sales growth-15.0% a year✗
Free cash flow growth—?
Return on invested capital-2.3%✗

Follow BNTX

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds BNTX. Who we track

Dodge & Cox Funds

Dodge & Cox Funds · as of Q2 2026

$342.2M

3,677,591 shares

Insider activity

Since Sep 3, 2026: no open-market purchases and 5 sales worth $17.1M. Why purchases matter

Sales

Sahin Ugur

Chief Executive Officer · 2026-09-10

Sold

$2.0M

Sahin Ugur

Chief Executive Officer · 2026-09-09

Sold

$3.5M

Sahin Ugur

Chief Executive Officer · 2026-09-08

Sold

$3.7M

Sahin Ugur

Chief Executive Officer · 2026-09-04

Sold

$3.3M

Sahin Ugur

Chief Executive Officer · 2026-09-03

Sold

$4.6M

About BioNTech SE

BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works